STOCK TITAN

Ping An Biomedical regains Nasdaq bid-price compliance

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
6-K

Rhea-AI Filing Summary

Ping An Biomedical Co., Ltd. (PASW) regained compliance with Nasdaq’s minimum bid-price requirement after its ordinary shares closed at $1.00 per share or greater for 10 consecutive business days, from November 2 through November 13, 2026. Nasdaq notified the company on November 16, 2026, and closed the prior bid-price deficiency matter.

Minimum closing bid price $1.00 per share Ordinary shares met or exceeded this level during the 10 consecutive business days from November 2 through November 13, 2026.
Compliance period 10 consecutive business days The closing bid price was at least $1.00 per share from November 2 through November 13, 2026.
Nasdaq Minimum Bid Price Requirement regulatory
"regained compliance with the Nasdaq Minimum Bid Price Requirement"
A Nasdaq minimum bid price requirement is a rule that a stock must trade above a set lowest share price (commonly $1) over a defined period to remain listed. It matters to investors because falling below that floor can trigger warnings, potential delisting, or corrective steps by the company — similar to failing to meet a grade that risks losing enrollment — which can reduce liquidity, access, and share value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Did PASW regain Nasdaq’s minimum bid-price compliance?

Yes. Nasdaq notified Ping An Biomedical on November 16, 2026, that it had regained compliance after its ordinary shares closed at $1.00 per share or greater for 10 consecutive business days, from November 2 through November 13, 2026. Nasdaq closed the prior bid-price deficiency matter.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

 

  

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of November, 2026

 

Commission File Number: 001-42155

 

Ping An Biomedical Co., Ltd.

 

(Registrant’s Name)

 

22/F, China United Plaza, 1002-1008, Tai Nan West Street,

Cheung Sha Wan, Kowloon, Hong Kong

(Address of Principal Executive Offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

 

Form 20-F ☒     Form 40-F ☐

 

 

 

 

Notice of Regained Compliance with Nasdaq Listing Rules

 

As previously disclosed, on November 24, 2025, Ping An Biomedical Co., Ltd. (the “Company”) received a letter from the Listing Qualifications staff of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that the bid price of the Company had closed at less than $1 per share over the previous 30 consecutive business days, and, as a result did not comply with Listing Rule 5550(a)(2).

 

Also as previously disclosed, the Company received a letter from Nasdaq on May 26, 2026, noting that while the Company’s listed security has not regained compliance with the minimum $1 bid price per share requirement, Staff has determined that the Company is eligible for an additional 180 calendar day period, or until November 23, 2026, to regain compliance. Nasdaq’s determination is based on the Company meeting the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on the Capital Market with the exception of the bid price requirement, and the Company’s written notice of its intention to cure the deficiency during the second compliance period by effecting a reverse stock split, if necessary. If at any time during this additional time period the closing bid price of the Company’s security is at least $1 per share for a minimum of 10 consecutive business days, Nasdaq will provide written confirmation of compliance and the matter will be closed.

 

On November 16, 2026, the Company received formal notification from Nasdaq, that the Company has regained compliance with the Nasdaq Minimum Bid Price Requirement. Nasdaq made this determination of compliance after the closing bid price of the Company’s ordinary shares was at $1.00 per share or greater for the last 10 consecutive business days from November 2, 2026 to November 13, 2026. Accordingly, the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2) and Nasdaq considers the prior bid price deficiency matter now closed.

  

1

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 
PING AN BIOMEDICAL CO., LTD.
     
Date: November 17, 2026 By: /s/ Pijun Liu
  Name:  Pijun Liu
  Title: Chairperson of the Board of Directors

 

2

 

 

Keep reading